- •Health-system specialty pharmacy (HSSP) patients had high adherence and persistence.
- •Switching DMTs was associated with lower adherence and persistence.
- •HSSPs are uniquely positioned to provide comprehensive care for patients with MS.
Though there are several disease-modifying therapy (DMT) options for patients with multiple sclerosis (MS), treatment outcomes rely on patient adherence and persistence. Previous studies have demonstrated suboptimal adherence rates and high rates of early treatment discontinuation. Health-system specialty pharmacies (HSPPs) are a growing practice model that have demonstrated adherence and persistence benefits through single site evaluations. Research is needed across multiple HSSPs to understand and validate the outcomes of this practice model.
A multisite prospective cohort study was performed including patients with at least three fills of a DMT between January 2020 and June 2021 at an HSSP. Patients were excluded due to pregnancy or death. Enrollment occurred for 6 months followed by 12 months of follow-up. Adherence was measured using pharmacy claims to calculate proportion of days covered (PDC) during the follow-up period. Time to non-persistence was calculated as the time from an index DMT fill to the first date of a gap of >60 days between medication exhaust and fulfillment dates. Adherence and persistence calculations were assessed at the therapeutic class level (any self-administered DMT dispensed by the HSSPs). The Kaplan-Meier method was used to present the probability of being persistent, and Cox proportional hazards regression analysis was used to estimate hazard ratios of factors associated with non-persistence, which included age, sex, study site, insurance type, and whether the patient switched medication as potential factors.
The most common self-administered DMTs filled among 968 patients were glatiramer acetate (32%), fingolimod (18%), and dimethyl fumarate (18%). Most patients (96%) did not switch DMT during the study period. The median PDC was 0.97 (interquartile range 0.90–0.99), which was similar across all sites. Patients who had at least one DMT switch were 76% less likely to have a higher PDC than those who did not have any switch after adjusting for other covariates (Odds ratio: 0.24, 95% confidence interval [CI]: 0.14–0.40, p<0.001). Most patients (86%) were persistent to DMT over the 12-month study period. Among those non-persistent, median time to non-persistence was 231 (IQR 177–301) days. Patients who switched medications were 2.4 times more likely to be non-persistent (95% CI: 1.3 - 4.5, p = 0.005). The most common reasons for non-persistence were discontinuation/medication held for an extended period (30%), often due to patient or prescriber decision (75%).
High rates of DMT adherence and persistence were seen among patients serviced by HSSPs, indicating potential benefits of this model for patients with MS. Switching DMTs was associated with lower adherence and persistence and may be an opportunity for added care coordination or resources to optimize therapy transitions.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Treatment of multiple sclerosis: a review.Am. J. Med. 2020; 133 (12.e2): 1380-1390https://doi.org/10.1016/j.amjmed.2020.05.049
- Diagnosis and treatment of multiple sclerosis: a review.JAMA. 2021; 325 (02 23): 765-779https://doi.org/10.1001/jama.2020.26858
- A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future.Inflamm. Res. 2019; 68 (Jan): 25-38https://doi.org/10.1007/s00011-018-1185-0
- Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Neurology. 2018; 90 (Apr 24): 777-788https://doi.org/10.1212/wnl.0000000000005347
- Medication compliance and persistence: terminology and definitions.Value Health. 2008; 11 (Jan-Feb): 44-47https://doi.org/10.1111/j.1524-4733.2007.00213.x
- Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.Pharmacoepidemiol. Drug Saf. 2017; 26 (Jun): 702-711https://doi.org/10.1002/pds.4207
- Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study.Neurol. Ther. 2022; (Sep 24)https://doi.org/10.1007/s40120-022-00404-1
- Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year.J. Manag. Care Spec. Pharm. 2017; 23 (Aug): 844-852https://doi.org/10.18553/jmcp.2017.23.8.844
- Disease progression in multiple sclerosis: a literature review exploring patient perspectives.Patient Prefer Adherence. 2021; 15: 15-27https://doi.org/10.2147/PPA.S268829
- Experiences of healthcare for people living with multiple sclerosis and their healthcare professionals.Health Expect. Int. J. Public Particip. Health Care Health Policy. 2021; 24 (12): 2047-2056https://doi.org/10.1111/hex.13348
- The association between persistence and adherence to disease-modifying therapies and healthcare resource utilization and costs in patients with multiple sclerosis.J. Health Econ. Outcomes Res. 2022; 9: 111-116https://doi.org/10.36469/jheor.2022.33288
- Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.J. Med. Econ. 2015; 18: 711-720https://doi.org/10.3111/13696998.2015.1044276
- Medication habits among persons with multiple sclerosis.Mult. Scler. Relat. Disord. 2022; 68 (Oct 07)104224https://doi.org/10.1016/j.msard.2022.104224
- A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.Mult. Scler. Relat. Disord. 2022; 63 (Jul)103860https://doi.org/10.1016/j.msard.2022.103860
- Medication adherence/persistence among patients with active multiple sclerosis in Finland.Acta Neurol. Scand. 2020; 142 (Dec): 605-612https://doi.org/10.1111/ane.13301
- ASHP National Survey of health-system specialty pharmacy practice-2020.Am. J. Health Syst. Pharm. 2021; 78: 1765-1791https://doi.org/10.1093/ajhp/zxab277
- Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.Am. J. Health Syst. Pharm. 2016; 73: 811-819https://doi.org/10.2146/ajhp150723
- Health-system specialty pharmacy role and outcomes: a review of current literature.Am. J. Health Syst. Pharm. 2022; (Aug 2)https://doi.org/10.1093/ajhp/zxac212
- The REDCap consortium: building an international community of Software platform partners.J. Biomed. Inform. 2019; 95 (Jul)103208https://doi.org/10.1016/j.jbi.2019.103208
- Research Electronic Data Capture (REDCap) - a metadata-driven Methodology and workflow process for providing translational research informatics support.J. Biomed. Inform. 2009; 42 (09/30): 377-381https://doi.org/10.1016/j.jbi.2008.08.010
- A language and Environment for Statistical Computing.R Foundation for Statistical Computing, 2022
- Adherence to Disease-Modifying Therapies At A Multiple Sclerosis Clinic: The Role Of The Specialty Pharmacist.J. Pharm. Pract. 2019; (Jan)897190018824821https://doi.org/10.1177/0897190018824821
- Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis.Am. J. Health Syst. Pharm. 2014; 71: 463-469https://doi.org/10.2146/ajhp130495
- Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis.Am. J. Health Syst. Pharm. 2014; 71 (Mar 15): 463-469https://doi.org/10.2146/ajhp130495
- Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.Adv. Ther. 2011; 28 (Sep): 761-775https://doi.org/10.1007/s12325-011-0054-9
- Facilitating medication adherence in patients with multiple sclerosis.Int. J. MS Care. 2013; 15: 36-45https://doi.org/10.7224/1537-2073.2011-038
- Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies.Am. J. Health Syst. Pharm. 2020; https://doi.org/10.1093/ajhp/zxaa135
- Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.J. Manag. Care Spec. Pharm. 2021; 27 (Oct): 1438-1446https://doi.org/10.18553/jmcp.2021.27.10.1438
- The effect of an integrated health system specialty pharmacy on HIV antiretroviral therapy adherence, viral suppression, and CD4 count in an outpatient infectious disease clinic.J. Manag. Care Spec. Pharm. 2020; 26 (2020/02/01): 95-102https://doi.org/10.18553/jmcp.2020.26.2.95
- Evaluation of a Hepatitis C patient management program at a University Specialty Pharmacy.Ann. Pharmacother. 2017; 51 (Apr): 307-314https://doi.org/10.1177/1060028016683495
- Adherence to therapy in patients with multiple sclerosis-review.Int. J. Environ. Res. Public Health. 2022; 19 (Feb 15)https://doi.org/10.3390/ijerph19042203
- Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.BMC Health Serv. Res. 2021; 21: 1141https://doi.org/10.1186/s12913-021-07012-z
- Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: a qualitative analysis.Mult. Scler. Relat. Disord. 2020; 41 (Jun)102016https://doi.org/10.1016/j.msard.2020.102016
- Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects.Cells. 2021; 10 (Nov 15)https://doi.org/10.3390/cells10113177
- Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: a cross-sectional study.Mult. Scler. Relat. Disord. 2021; 50 (May)102856https://doi.org/10.1016/j.msard.2021.102856
- Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study.Mult. Scler. 2017; 23 (Apr): 588-596https://doi.org/10.1177/1352458516657440
- Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.J. Manag. Care Spec. Pharm. 2021; 27 (Jun): 732-742https://doi.org/10.18553/jmcp.2021.27.6.732
- Development and implementation of a laboratory monitoring dashboard to reduce treatment gaps in inflammatory bowel disease.Am. J. Health Syst. Pharm. 2022; (Nov 26)https://doi.org/10.1093/ajhp/zxac354
- Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.J. Manag. Care Spec. Pharm. 2021; 27 (May): 639-649https://doi.org/10.18553/jmcp.2021.20413
- Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.J. Manag. Care Spec. Pharm. 2021; 27 (Sep): 1273-1295https://doi.org/10.18553/jmcp.2021.27.9.1273
- Factors leading patients to discontinue multiple sclerosis therapies.J. Am. Pharm. Assoc. (2003). 2005; 45 (May-Jun 2005): 371-375https://doi.org/10.1331/1544345054003804
- Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network.Front. Neurol. 2021; 12647811https://doi.org/10.3389/fneur.2021.647811
- Telephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosis.Rehabil. Psychol. 2014; 59 (May): 136-146https://doi.org/10.1037/a0036322
- Factors that influence adherence with disease-modifying therapy in MS.J. Neurol. 2009; 256 (Apr): 568-576https://doi.org/10.1007/s00415-009-0096-y
- An integrated health-system specialty pharmacy model for coordinating transitions of care: specialty medication challenges and specialty pharmacist opportunities.Pharmacy. 2019; 7 (Basel). Dec 3https://doi.org/10.3390/pharmacy7040163
- Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies.Continuum. 2019; 25 (Minneap Minn). Jun: 715-735https://doi.org/10.1212/CON.0000000000000738
Published online: April 28, 2023
Accepted: April 27, 2023
Received in revised form: April 19, 2023
Received: December 30, 2022
© 2023 Elsevier B.V. All rights reserved.